Immunotherapy is showing good results in patients with advanced skin cancer, one of the most common types of cancer diagnosed in the United States.
Skin CancerPatient Stories
Mark Ryan, RN, is not worried about the impact of climate change on the weather, but on skin cancer, which he knows first-hand. A decrease in stratospheric ozone requires stringent environmental regulations to prevent cancer, he says.
FDA Approvals, News & UpdatesSkin Cancer
The immunotherapy Libtayo is a new treatment option for advanced or metastatic basal-cell carcinoma, a type of skin cancer. Libtayo was initially approved for a different type of skin cancer.
Skin CancerCancer Screening
Dr. Andrew Weinstein, a dermatologist, stresses the importance of monitoring skin changes regularly, giving advice and information regarding skin cancer, the most common cancer in the USA.
ImmunotherapyPatient StoriesSkin Cancer
Chris Andersen learned the value of trusting one’s instincts and asking for a second opinion after receiving a misdiagnosis of breast cancer that was later diagnosed as metastatic skin cancer and she was told she had 1 to 2 years to live. Thanks to a new treatment for skin cancer, she now has no signs of cancer.
New results presented at the 2020 ASCO annual meeting show that patients with advanced or metastatic (spreading) cutaneous squamous-cell carcinoma (CSCC) who received the PD-1 inhibitor Libtayo (cemiplimab) lived much longer than patients who did not receive this PD-1 inhibitor.
Libtayo Reduces Pain, Improves Quality of Life in Patients with Advanced Cutaneous Squamous-Cell Carcinoma
This article reviews the promising findings presented at the 2020 ASCO meeting showing that treatment with the immunotherapy Libtayo may reduce pain and improve survival without disease progression in patients with advanced cutaneous squamous-cell carcinoma, or skin cancer.
Immunotherapy with Libtayo Prolongs Survival in Patients with Metastatic Cutaneous Squamous-Cell Carcinoma
Cutaneous squamous-cell carcinoma (CSCC), or skin cancer, is the second most common cancer in the United States. This article examines the results of a recent study on the first and only immunotherapy approved for patients with advanced or metastatic CSCC.
Page 1 of 2
Results 1 - 10 of 20
Results 1 - 10 of 20